|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07C 271/16 | |
| C07C 271/20 | |||
| C07D 213/64 |
| (11) | Number of the document | 2457893 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11009050.3 |
| Date of filing the European patent application | 2005-06-13 | |
| (97) | Date of publication of the European application | 2012-05-30 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-16 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 872142 | 2004-06-18 | US | |
| 621642 P | 2004-10-26 | US | |
| 622005 P | 2004-10-27 | US | |
| 642271 P | 2005-01-07 | US | |
| 149731 | 2005-06-10 | US |
| (72) |
Hoveyda, Hamid, BE
Peterson, Mark L., CA
Fraser, Graeme, BE
Ramaseshan, Mahesh, US
|
| (73) |
Ocera Therapeutics, Inc.,
525 University Avenue, Suite 610, Palo Alto, CA 94301,
US
|
| (54) | Intermediates for macrocyclic modulators of the ghrelin receptor |
| Intermediates for macrocyclic modulators of the ghrelin receptor |